Principia Biopharma Inc. (PRNB)
(Delayed Data from NSDQ)
$30.40 USD
+1.38 (4.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $30.41 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[PRNB]
Reports for Purchase
Showing records 1 - 20 ( 23 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Monday Morning Surprise...Well Not Really; Sanofi Acquires Principia; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Moons Are Really Aligning to Us; PT Upped to $108
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Sanofi Starts MS Phase 3 Program; Principia About to Cash a $50M Check
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
ITP Update Confirms Our Confidence in Rilzabrutinib
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Sanofi Delivers on MS Phase 2b Data as Broad Phase 3Program About to Get Cranking.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Reiterate Core Name for Post-COVID-19 Rebound; Takeout in the Future?
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
2019 Results; Continued Strong Fundamentals in Volatile Markets
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Continued Evidence That the Drugs Work; Target Increased to $70
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Success Also Breeds Naysayers and Inaccuracies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Further BTK Expansion; Sanofi''s Important MS Data Expected This Quarter; Target Tweaked to $62
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Rilzabrutinib Expansion Continues; Preliminary 2020 Outlook; Target Upped to $63
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
3Q19 Results; Expect Strong ITP Update at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Early and Impressive ITP Data as Well as Topping Off Coffers; Target Increased to $57
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Consistency Is the Message of the Day for PV Efficacy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Don''t Forget; PV and ITP Key Data Catalysts Not Too Far Off
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J